iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
02. März 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., March 02, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is...
iCAD to Present at the 42nd Annual Cowen Health Care Conference
01. März 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., March 01, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the...
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021
28. Februar 2022 16:05 ET
|
iCAD, Inc.
Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation Demonstrated compelling survival data for the use of Xoft® Brain IORT in...
iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28
14. Februar 2022 16:05 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08. Februar 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 08, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company...
iCAD’s Breast AI Platform Earns U.S. Department of Defense Authorization to Operate
24. Januar 2022 14:25 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 24, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the...
iCAD Announces the Appointment of New Members to its Board of Directors
11. Januar 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 11, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has...
iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues
04. Januar 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 04, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select...
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event
23. Dezember 2021 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States
14. Dezember 2021 08:00 ET
|
iCAD, Inc.
Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor ...